Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
about
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172FAF-Drugs3: a web server for compound property calculation and chemical library design.Drug discovery beyond the rule of 5 - Opportunities and challenges.Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules.Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs.Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products.Computational allosteric ligand binding site identification on Ras proteins.Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitorsStrengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Why we need to implement intramolecular hydrogen-bonding considerations in drug discovery.The forgotten or underestimated relevance of biopharmaceutical-based assessments for the oral absorption studies of oxime reactivators.Non-coding RNAs as drug targets.Inhibition of Protein-Protein Interactions: New Options for Developing Drugs against Neglected Tropical Diseases.Multivalent Inhibitors of Channel-Forming Bacterial Toxins.Oral Administration of Peptide-Based Drugs: Beyond Lipinski's Rule.Large-scale classification of P-glycoprotein inhibitors using SMILES-based descriptors.Structural and conformational determinants of macrocycle cell permeability.Stereochemistry Balances Cell Permeability and Solubility in the Naturally Derived Phepropeptin Cyclic Peptides.Increased Conformational Flexibility of a Macrocycle-Receptor Complex Contributes to Reduced Dissociation Rates.Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs.Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery.Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application.Catalytic sp3 -sp3 Functionalisation of Sulfonamides: Late-Stage Modification of Drug-Like Molecules.Cannabinoid Type 1 Receptor (CB1) Ligands with Therapeutic Potential for Withdrawal Syndrome in Chemical Dependents of Cannabis sativa.A Molecular Docking and Dynamics Approach to Screen Potent Inhibitors Against Fosfomycin Resistant Enzyme in Clinical Klebsiella pneumoniae.Covalent Strategies for Targeting Messenger and Non-Coding RNAs: An Updated Review on siRNA, miRNA and antimiR Conjugates.Prediction and interpretation of the lipophilicity of small peptides.Tyr1-ψ[( Z)CF═CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin.Divergent solid-phase synthesis of natural product-inspired bipartite cyclodepsipeptides: total synthesis of seragamide A.Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization.Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?Challenging the Drug-Likeness Dogma for New Drug Discovery in TuberculosisEvolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
P2860
Q27703170-788D4B51-9E87-4D7C-9FB0-D33D2CCD09F0Q35604907-CEB23454-0967-4619-A534-B05289CE4177Q36203347-7B3AE341-D485-4BDF-8288-A1EFE775D626Q36242161-ADC53D4E-CABB-40E3-93C0-D80B4698850DQ36517549-4BEA6F1E-9385-4E36-8BE6-029C80341646Q37532708-FE409490-D9C0-4C9F-93E8-94BD172D9D1BQ38612789-A7D8C73B-5BEB-400D-98AC-1211099D5789Q38732067-21FD062B-B371-4E62-8AF9-42E911175C28Q38750666-8AC85033-234C-422F-B539-C2CDEABCB0E9Q38783642-11CB4857-1892-47DD-9340-77D7A9490D99Q38825239-B609B54E-9948-4995-84F2-A4336773EA7FQ38904908-9BC783BA-EF2F-452F-9DEF-D5B13A702F5DQ38904985-E90A8F53-CC3C-44B0-9CDF-A8AFD0845F4DQ38911726-D257C9CD-CEE0-43F8-85E2-06B064A21A2CQ38946802-96EAA0AC-1947-4343-B2EC-F1EFC682D9B2Q39038015-13334BE5-F7F6-4724-AA4E-0C9213F01AD7Q39283186-09A07DBA-D06B-433F-B4A9-AF2263E16418Q42358786-CA6E8EDD-C4CF-407C-A981-147244BB982FQ47095079-3606ADFB-FEFD-4DB1-9E73-C7FC64826483Q47324655-4C8051A9-393D-4721-9F52-39D7C2DE9B6BQ47849835-11F2B2B0-2A0C-4351-AD25-7B54BB83A675Q48113002-BC7D2499-EA16-4533-B26E-F69D62B461D1Q48191285-E10E9D69-A5BC-4FBF-8B27-DF9CF0B87742Q48267092-80EEE934-B3DE-4B23-A522-52E3343E9917Q48274337-4B044B04-EA99-4803-960B-DBD838AAB608Q50131778-661E276B-71F3-4C16-84F5-9AD99FCA62AFQ50978597-6A41C000-136F-45C8-9483-255C58E5F947Q52592115-135F79FD-0A4A-4E07-BD0A-83A1549C1612Q52792912-EFC3912D-4BBE-47B7-B15E-E58A30BCAE1EQ55365073-C6AB4A16-C42B-409C-8269-9BEF8BFEBEC7Q57489617-5F4380CB-F5AB-495E-A433-410A7B6868C9Q57656314-ED3DD10D-1233-46E2-8FE6-1D776188D938Q58697064-016655DF-4708-4339-AF14-6768D01FC02E
P2860
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@ast
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@en
type
label
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@ast
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@en
prefLabel
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@ast
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
@en
P1476
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates
@en
P2093
Fabrizio Giordanetto
Jan Kihlberg
P304
P356
10.1016/J.CHEMBIOL.2014.08.013
P577
2014-09-01T00:00:00Z